findmyKOL

John Cush, MD

Enriched profile

Executive Editor, RheumNow.com; Professor of Internal Medicine, TCU Burnett School of Medicine · TCU Burnett School of Medicine

ORCIDNone on fileNPI↗
✓ Full profile
Region🇺🇸 Dallas, TX · South Central · United StatesSpecialtyRheumatologyFocusRheumatoid Arthritis
Active KOLfindmyKOL type: EliteLatest publication2022Online presenceverified 2026Payments2021–2025NIH funding1995–1999Why? →

John Cush is Executive Editor, RheumNow.com; Professor of Internal Medicine, TCU Burnett School of Medicine at TCU Burnett School of Medicine. ClinicalTrials.gov lists 1 registered study with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 18 Oct 2026

John Cush, MD, is Executive Editor, RheumNow.com at TCU Burnett School of Medicine (Fort Worth, TX) / RheumNow.com. The public record shows 98 publications with 10,888 citations (h-index 41), centered on Rheumatoid Arthritis. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 18 companies, 1 NIH-funded awards (1995–1999).

  • Top research focus: Rheumatoid Arthritis
  • 1 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 18 companies

Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Rheumatoid Arthritis1 trial

Research focus

OpenAlex concept fingerprint
Rheumatoid Arthritis

Drugs & molecules

across trials, industry payments and publications
Tremfyageneric · GuselkumabClinical trials—Industry payments117Publications—Bimzelxgeneric · BimekizumabClinical trials—Industry payments33Publications—Humirageneric · AdalimumabClinical trials—Industry payments28Publications—Cosentyxgeneric · SecukinumabClinical trials—Industry payments20Publications—Ilarisgeneric · CanakinumabClinical trials—Industry payments20Publications—Rinvoqgeneric · UpadacitinibClinical trials—Industry payments16Publications—Lupkynisgeneric · VoclosporinClinical trials—Industry payments9Publications—Orenciageneric · AbataceptClinical trials—Industry payments5Publications—Cimziageneric · Certolizumab pegolClinical trials—Industry payments4Publications—Otezlageneric · ApremilastClinical trials—Industry payments4Publications—Otrexupgeneric · MethotrexateClinical trials—Industry payments2Publications—Actemrageneric · TocilizumabClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Novartis Pharmaceuticals CorporationClinical trials—Industry payments122Janssen Scientific Affairs, LLCClinical trials—Industry payments117Abbvie Inc.Clinical trials—Industry payments71E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments50Pfizer Inc.Clinical trials—Industry payments47UCB, Inc.Clinical trials—Industry payments41Genentech, Inc.Clinical trials—Industry payments19Aurinia Pharma U.S., Inc.Clinical trials—Industry payments9Amgen Inc.Clinical trials—Industry payments6Assertio Therapeutics, Inc.Clinical trials—Industry payments2AstraZeneca Pharmaceuticals LPClinical trials—Industry payments1Baylor Research InstituteClinical trials1Industry payments—Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trials—Industry payments1Genentech USA, Inc.Clinical trials—Industry payments1Lilly USA, LLCClinical trials—Industry payments1Medline Industries LPClinical trials—Industry payments1Ucb SaClinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
41h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials ↓
18companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 1995–1999

Federally funded research awards.

View funding ↓

Public positions

sourced statements on record

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 18 Oct 2026

Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:

Industry payments

Updated 18 Oct 2026

18 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2021)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    40.6%
    Opioid Agonist14.7%
    Tramadol Hcl100%
    Part D≥45 patients
    Gabapentinoids7.4%
    Gabapentin89%Pregabalin11%
    Part D<11 patients

    + 7 more classes in this area

  • Cancer & immunology

    21.7%
    Folate Analog Metabolic Inhibitor7.6%
    Methotrexate100%
    Part D≥36 patients
    TNF inhibitor5.7%
    Humira(Cf)36%Enbrel25%Humira(Cf) Pen21%Enbrel Sureclick17%
    Part D<11 patients

    + 4 more classes in this area

  • Musculoskeletal

    18.5%
    Xanthine oxidase inhibitor5.7%
    Allopurinol100%
    Part D≥20 patients
    Central alpha-2 Adrenergic Agonist5.2%
    Tizanidine Hcl100%
    Part D≥32 patients

    + 3 more classes in this area

All 5 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)8.1% facility · 91.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 18 Oct 2026

1 NIH research award on record, funded 1995–1999 per NIH RePORTER. The latest:

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Online presence

Updated 18 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/cv/john-cush-md-1

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗

Mentions by others

where others cite or feature them
  • Other

    rheumnow.com/team

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →rheumnow.com ↗
  • YouTube

    youtube.com/watch

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 18 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Executive Editor

    RheumNow.com

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →rheumnow.live ↗
  • Professor of Internal Medicine

    TCU Burnett School of Medicine, Fort Worth, TX

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tregmd.com ↗
  • Director of Clinical Rheumatology

    Baylor Research Institute

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tregmd.com ↗
  • Chairman

    Corporate Relations Committee, American College of Rheumatology

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ccrheumatology.com ↗
  • Chair

    Academic Board of Trustees, St. George's University School of Medicine

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ccrheumatology.com ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.